Treatment of Neurogenic Cough
For neurogenic cough, initiate gabapentin as first-line therapy after discussing side effects and risk-benefit profile with the patient, with reassessment at 6 months. 1
First-Line Pharmacologic Treatment
The 2016 CHEST guideline provides the strongest recommendation for gabapentin as the primary neuromodulator for unexplained chronic cough (neurogenic cough) 1. This recommendation is based on positive RCT evidence and achieved 90% expert panel approval. The guideline explicitly suggests:
- Start with gabapentin after thorough discussion of potential side effects
- Reassess the risk-benefit profile at 6 months
- Use dosing based on the Ryan et al RCT protocol 1
This guideline-based approach is strongly supported by current practice patterns, where 96.5% of laryngologists prescribe neuromodulators, with gabapentin being the preferred first-line agent (45.1% of practitioners) 2.
Alternative First-Line Options
Amitriptyline represents a reasonable alternative first-line choice, particularly if gabapentin is contraindicated or not tolerated:
- Used by 91.5% of laryngologists for chronic cough 2
- Second most preferred first-line agent (39.0%) 2
- Supported by positive RCT evidence, though the CHEST guideline did not make a formal recommendation 1
Tramadol has emerged as another effective option:
- 71% response rate (38% complete, 33% partial) in a 69-patient case series 3
- Most common successful dose: 50 mg twice daily 3
- Well-tolerated with sedation in only 10% 3
- Third most commonly used by laryngologists (73.2%) 2
Stepwise Treatment Algorithm
When initial neuromodulator therapy is successful:
- Continue for 3-6 months before making changes 2
- Wean to the lowest cough-controlling dose (68.3% of practitioners) 2
- 50% of complete responders can be successfully weaned off after mean 39 weeks (tramadol data) 3
When first-line neuromodulator fails:
- Wean and trial a different neuromodulator (43.9% of practitioners) 2
- Consider superior laryngeal nerve (SLN) block (24.4% of practitioners) 2
Procedural Interventions
Superior Laryngeal Nerve Block:
- Effective in 74.4% of patients with median 3 injections 4
- Consider after failed medical therapy 5, 2
- Median follow-up 4 weeks, with sustained improvement up to 40 months 4
- Mild adverse events in only 8.4% of injections 4
Botulinum toxin injections:
- Reserve for patients failing both neuromodulators and SLN block 5
- 67% response rate (6 of 9 patients) in stepwise approach 5
- Average response rating 2.4/5 5
Overall Treatment Success
A multimodal stepwise approach achieves 75% overall response rate 5:
- 58.9% respond to neuromodulators alone (average rating 3.0/5) 5
- Additional patients respond to SLN block or botulinum toxin 5
Therapies NOT Recommended
Proton pump inhibitors: The CHEST guideline explicitly recommends against PPI therapy in patients with negative workup for acid reflux disease (Grade 2C) 1. High-dose esomeprazole showed no benefit on cough severity or quality of life 1.
Important Caveats
Morphine was specifically rejected by the CHEST expert panel despite positive RCT evidence, failing to achieve the 80% approval threshold (only 75%) 1. While one recent study showed benefit in a specific genetic condition (RE-RFC1) 6, it should only be considered when all other options have failed.
Adverse effects of neuromodulators can be significant and limit maximum tolerable doses 1
Patients with history of laryngeal surgery are less likely to respond to tramadol (p = 0.04) 3
If cough recurs after successful weaning, 97.6% of laryngologists reinitiate the previously effective neuromodulator 2